FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2144233480> ?p ?o ?g. }

• W2144233480 endingPage "700" @default.
• W2144233480 startingPage "691" @default.
• W2144233480 abstract "Abstract Purpose: Overexpression of the ErbB family of receptor tyrosine kinases has been associated with uncontrolled growth of many tumor types and, therefore, presents a promising molecular target for cancer therapy. CI-1033 is a small molecule tyrosine kinase inhibitor that differs from other 4-anilinoquinazolines by being a pan ErbB (instead of epidermal growth factor receptor-specific) irreversible (instead of reversible) inhibitor. Therefore, we investigated the antitumor effect of CI-1033 alone and in combination with ionizing radiation in vitro and in vivo. Experimental Design: We selected three human colon carcinoma cell-lines (LoVo, Caco-2, which express activated epidermal growth factor receptor and ErbB-2 family members, and SW620, which does not), and analyzed the effects of CI-1033 both in vitro and in vivo. For in vivo studies LoVo and Caco-2 cells were implanted s.c. in the flank of nude mice. After the tumor reached ∼100 mm3, treatment was initiated with 20 mg/kg of CI-1033 (orally once daily × 5 for 3 successive weeks), radiation treatment (a total of 30 Gy given in 2 Gy once daily × 5 for 3 successive weeks), or a combination of both CI-1033 and radiation treatment. Results: We found that exposure of LoVo and Caco-2, but not SW620 cells, to CI-1033 in the range of 1–3 μm could inhibit constitutive signaling by tyrosine kinases, arrest cell growth, inhibit cells in G1, stimulate expression of p53, and induce apoptosis. The inhibition of cell growth by CI-1033 seemed to produce only minimal radiosensitization in LoVo and Caco-2 cells. In contrast, the combination of CI-1033 and radiation produced significant (P &lt; 0.0005 and P = 0.0002, respectively) and prolonged suppression of tumor growth in both the tumor types when compared with either treatment alone. Conclusions: These findings suggest that CI-1033 can increase the effectiveness of radiation therapy. The extent of suppression of tyrosine kinase activity by CI-1033, rather than the amount of activity in untreated cells, seemed to be more closely associated with the efficacy of combination treatment." @default.
• W2144233480 created "2016-06-24" @default.
• W2144233480 creator A5003311852 @default.
• W2144233480 creator A5028395389 @default.
• W2144233480 creator A5029175020 @default.
• W2144233480 creator A5029461614 @default.
• W2144233480 creator A5032791667 @default.
• W2144233480 creator A5046132413 @default.
• W2144233480 creator A5052076870 @default.
• W2144233480 creator A5057594429 @default.
• W2144233480 creator A5084941880 @default.
• W2144233480 date "2004-01-15" @default.
• W2144233480 modified "2023-10-14" @default.
• W2144233480 title "Radiosensitization by Pan ErbB Inhibitor CI-1033 <b> <i>in Vitro</i> </b> and <b> <i>in Vivo</i> </b>" @default.
• W2144233480 cites W141627170 @default.
• W2144233480 cites W1527076593 @default.
• W2144233480 cites W1991322491 @default.
• W2144233480 cites W2001598945 @default.
• W2144233480 cites W2002859032 @default.
• W2144233480 cites W2006720018 @default.
• W2144233480 cites W2014134684 @default.
• W2144233480 cites W2019691808 @default.
• W2144233480 cites W2025884076 @default.
• W2144233480 cites W2035722698 @default.
• W2144233480 cites W2039231974 @default.
• W2144233480 cites W2051120695 @default.
• W2144233480 cites W2054617643 @default.
• W2144233480 cites W2064047613 @default.
• W2144233480 cites W2066655424 @default.
• W2144233480 cites W2075962843 @default.
• W2144233480 cites W2080414061 @default.
• W2144233480 cites W2085254573 @default.
• W2144233480 cites W2090871977 @default.
• W2144233480 cites W2110866673 @default.
• W2144233480 cites W2125735022 @default.
• W2144233480 cites W2150059798 @default.
• W2144233480 cites W2319139826 @default.
• W2144233480 cites W2411241259 @default.
• W2144233480 cites W4237989280 @default.
• W2144233480 doi "https://doi.org/10.1158/1078-0432.ccr-1041-03" @default.
• W2144233480 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14760092" @default.
• W2144233480 hasPublicationYear "2004" @default.
• W2144233480 type Work @default.
• W2144233480 sameAs 2144233480 @default.
• W2144233480 citedByCount "80" @default.
• W2144233480 countsByYear W21442334802012 @default.
• W2144233480 countsByYear W21442334802013 @default.
• W2144233480 countsByYear W21442334802014 @default.
• W2144233480 countsByYear W21442334802015 @default.
• W2144233480 countsByYear W21442334802016 @default.
• W2144233480 countsByYear W21442334802018 @default.
• W2144233480 countsByYear W21442334802019 @default.
• W2144233480 countsByYear W21442334802020 @default.
• W2144233480 countsByYear W21442334802023 @default.
• W2144233480 crossrefType "journal-article" @default.
• W2144233480 hasAuthorship W2144233480A5003311852 @default.
• W2144233480 hasAuthorship W2144233480A5028395389 @default.
• W2144233480 hasAuthorship W2144233480A5029175020 @default.
• W2144233480 hasAuthorship W2144233480A5029461614 @default.
• W2144233480 hasAuthorship W2144233480A5032791667 @default.
• W2144233480 hasAuthorship W2144233480A5046132413 @default.
• W2144233480 hasAuthorship W2144233480A5052076870 @default.
• W2144233480 hasAuthorship W2144233480A5057594429 @default.
• W2144233480 hasAuthorship W2144233480A5084941880 @default.
• W2144233480 hasConcept C101544691 @default.
• W2144233480 hasConcept C121608353 @default.
• W2144233480 hasConcept C126322002 @default.
• W2144233480 hasConcept C150903083 @default.
• W2144233480 hasConcept C170493617 @default.
• W2144233480 hasConcept C190283241 @default.
• W2144233480 hasConcept C202751555 @default.
• W2144233480 hasConcept C207001950 @default.
• W2144233480 hasConcept C26375932 @default.
• W2144233480 hasConcept C2776362946 @default.
• W2144233480 hasConcept C2778820342 @default.
• W2144233480 hasConcept C2779251935 @default.
• W2144233480 hasConcept C2779438470 @default.
• W2144233480 hasConcept C42362537 @default.
• W2144233480 hasConcept C502942594 @default.
• W2144233480 hasConcept C55493867 @default.
• W2144233480 hasConcept C71924100 @default.
• W2144233480 hasConcept C86803240 @default.
• W2144233480 hasConcept C98274493 @default.
• W2144233480 hasConceptScore W2144233480C101544691 @default.
• W2144233480 hasConceptScore W2144233480C121608353 @default.
• W2144233480 hasConceptScore W2144233480C126322002 @default.
• W2144233480 hasConceptScore W2144233480C150903083 @default.
• W2144233480 hasConceptScore W2144233480C170493617 @default.
• W2144233480 hasConceptScore W2144233480C190283241 @default.
• W2144233480 hasConceptScore W2144233480C202751555 @default.
• W2144233480 hasConceptScore W2144233480C207001950 @default.
• W2144233480 hasConceptScore W2144233480C26375932 @default.
• W2144233480 hasConceptScore W2144233480C2776362946 @default.
• W2144233480 hasConceptScore W2144233480C2778820342 @default.
• W2144233480 hasConceptScore W2144233480C2779251935 @default.
• W2144233480 hasConceptScore W2144233480C2779438470 @default.
• W2144233480 hasConceptScore W2144233480C42362537 @default.
• W2144233480 hasConceptScore W2144233480C502942594 @default.

• next